These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12113231)

  • 1. Dynavax and Coley Pharmaceutical Group initiate rituximab combination trials.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):138. PubMed ID: 12113231
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Maintenance therapy with rituximab].
    Krankenpfl J; 2005; 43(7-10):222-4. PubMed ID: 16515293
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for the treatment of diffuse large B-cell lymphomas.
    Held G; Pöschel V; Pfreundschuh M
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and safety of rituximab (MabThera).
    Kimby E
    Cancer Treat Rev; 2005 Oct; 31(6):456-73. PubMed ID: 16054760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHOP and rituximab in elderly patients.
    Portlock CS
    Curr Oncol Rep; 2002 Sep; 4(5):414. PubMed ID: 12162916
    [No Abstract]   [Full Text] [Related]  

  • 11. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
    Ahmadi T; Schuster SJ
    J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
    [No Abstract]   [Full Text] [Related]  

  • 12. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse large B-cell lymphoma.
    Ng AK
    Semin Radiat Oncol; 2007 Jul; 17(3):169-75. PubMed ID: 17591563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
    Miles SA; McGratten M
    J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment strategy for indolent B-cell lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2001 Apr; 42(4):288-92. PubMed ID: 11400299
    [No Abstract]   [Full Text] [Related]  

  • 17. Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.
    Friedberg JW
    Clin Cancer Res; 2004 Aug; 10(16):5297-8. PubMed ID: 15328164
    [No Abstract]   [Full Text] [Related]  

  • 18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing rituximab in B-cell lymphoma.
    Horning SJ
    J Clin Oncol; 2005 Feb; 23(6):1056-8. PubMed ID: 15657408
    [No Abstract]   [Full Text] [Related]  

  • 20. Generalized B-cell non Hodgkin's lymphoma in association with leukocytoclastic vasculitis and disseminated intravascular coagulation.
    Cardinali C; Santini S; di Leo A; Giannini A; Lo Scocco G
    Dermatol Online J; 2006 Mar; 12(3):15. PubMed ID: 16638429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.